PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.285 AUD -1.91% Market Closed
Market Cap: 599.6m AUD
Have any thoughts about
PYC Therapeutics Ltd?
Write Note

P/FCFE
Price to FCFE

-15.5
Current
-22.3
Median
24.2
Industry
Higher than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-15.5
=
Market Cap
606.8m AUD
/
FCFE
-39.1m AUD
All Countries
Close
Market Cap P/FCFE
AU
PYC Therapeutics Ltd
ASX:PYC
606.8m AUD -15.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 204 866.1
US
Abbvie Inc
NYSE:ABBV
340.8B USD 13.7
US
Amgen Inc
NASDAQ:AMGN
156.4B USD 26.4
US
Gilead Sciences Inc
NASDAQ:GILD
129.7B USD 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.9B USD -124.7
US
Epizyme Inc
F:EPE
94.1B EUR -428.2
AU
CSL Ltd
ASX:CSL
124.4B AUD 71.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.8B USD 21.2
US
Seagen Inc
F:SGT
39.3B EUR -58.9
NL
argenx SE
XBRU:ARGX
36.3B EUR -115.3
 
AU
PYC Therapeutics Ltd
ASX:PYC
Average P/FCFE: 29.2
Negative Multiple: -15.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 204 866.1
US
Abbvie Inc
NYSE:ABBV
13.7
US
Amgen Inc
NASDAQ:AMGN
26.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -124.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -428.2
AU
CSL Ltd
ASX:CSL
71.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
21.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9
NL
argenx SE
XBRU:ARGX
Negative Multiple: -115.3

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A